Omnix Medical raises $25 million Series C to tackle drug-resistant infections
11.20.2025 | Avi
15/10/2025
Tel Aviv, Israel
Israeli biotech secures funding to complete Phase II trials for its novel antimicrobial peptide therapy.
https://www.calcalistech.com/ctechnews/article/hjqrmrnpgl